부산대학교 도서관

Primary central nervous system lymphoma (PCNSL) is an aggressive subtype of non-Hodgkin lymphoma that carries a poor prognosis in the elderly. The aim of this study is to investigate treatment patterns and survival trends in patients ≥ 65 years with PCNSL through data provided by the Texas Cancer Registry. Adults ≥ 65 years diagnosed with PCNSL and followed between 1995–2017 were identified and separated into three eras: 1995–2003, 2004–2012, and 2013–2017. Baseline covariates compared included patient demographics and treatments administered. Pearson's chi-squared test and Cox proportional hazard models compared covariates; overall survival (OS) and disease-specific survival (DSS) were assessed via Kaplan–Meier methodology. There were 375 patients; 104 (27.7%) in 1995–2003, 146 (38.9%) in 2004–2012, and 125 (33.3%) in 2013–2017. There were 50 (48.1%), 55 (37.7%), and 31 (24.8%) in 1995–2003, 2004–2012, and 2013–2017, respectively, that did not receive treatment. At last follow up, 101 (97.1%), 130 (89.0%), and 94 (75.2%) in each era died, of which 89 (85.6%), 112 (76.7%), and 70 (56.0%) were attributed to PCNSL. Median OS per era was eight (95% confidence interval [CI] 5.06–10.93), six (95% CI, 2.30–9.69), and five months (95% CI, 2.26–7.73) (p = 0.638). DSS per era was nine (95% CI: 0.00, 26.53), 10 (95% CI: 5.14, 14.86), and 19 (95% CI, 0.00–45.49) (p = 0.931) months. Spinal cord as primary disease site (HR: 0.668 [95% CI, 0.45–0.99], p = 0.049), and chemotherapy (HR 0.532 [95% CI, 0.42–0.673], p = < 0.001) or chemotherapy + radiation (HR, 0.233 [95% CI, 0.11–0.48] p < 0.001) had better outcomes compared to no therapy or radiation therapy alone. Survival in older patients ≥ 65 with PCNSL has not improved per our analysis of the TCR from 1995–2017 despite increasing trends of treatment utilization. Strategies to augment recruitment of older individuals in trials are needed in order to determine who would derive treatment benefit and minimize treatment toxicities. [ABSTRACT FROM AUTHOR]